Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Remember when I said cha Ching in May ?

<< Previous

Bullboard Posts

Next >>

Comment by WORKINMONTANAon May 13, 2020 12:19pm

286 Views

Post# 31022806

RE:Remember when I said cha Ching in May ?

Hillbilly that is. Set a spell, Take your shoes off.

Y'all come back now, y'hear?

scaley wrote: Obviously it's going to be good news. Everything happens for a reason. They are broke, but the test results have been stellar. Remember when Jed Clampett was hunting ? and missed the rabbit , but struck oil? Same thing here

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program